Abstract: Background: The effectiveness of trivalent influenza vaccination has been confirmed in several studies. To date, it is not known whether repeated exposure and vaccination to influenza promote production of cross-reactive anti-bodies. Furthermore, how strains encountered earlier in life imprint the immune response is currently poorly understood. Methods: To determine the prevalence for human homo-and heterosubtypic antibody responses, we scruti-nized serum samples from 305 healthy volunteers for hemagglutinin-binding and -neutralizing antibodies against several strains and subtypes of influenza A. Statistical analyses were then performed to establish the association of measured values with potential predictors. Results: It was found that vaccination not only promoted higher binding and neutralizing antibody titers to homosubtypic in fluenza isolates but also increased heterosubtypic human immune responses. Both binding and neutralizing antibody titers in relation with age of the donors mirrored the course of the different influenza strain circulation during the last century. Advanced age appeared to be of advantage for both binding and neutralizing titers to most subtypes. In contrast, the first virus subtype encountered was found to imprint to some degree subsequent antibody responses. Antibodies to recent strains, however, primarily seemed to be promoted by vaccination. Conclusions: We provide evidence that vaccinations stimulate both homo-and heterosubtypic immune responses in young and middle-aged as well as more senior individuals. Our analyses suggest that influenza vaccinations not only prevent infection against currently circulating strains but can also stimulate broader humoral immune responses that potentially attenuate infections with zoonotic or antigenically shifted strains. 
Background
The antibody response to influenza viruses is highly strain-and subtype-specific, and is primarily directed against the variable immunodominant apical epitopes on the hemagglutinin (HA) protein [1] . Vaccine-induced antibodies are therefore only effective against viruses closely related to the inoculated strains, and immunization needs to be revised annually in order to reflect the antigenic outfit of the viruses predicted to be predominant in the following influenza season. The breadth of the anti-influenza virus antibody response is further limited by the original antigenic sin (OAS) in that every immunization also boosts the memory response to the priming strain [2] . Indeed, Lessler and colleagues stated that in humans repeated exposure to different H3N2 strains increased antibody titers to strains encountered earlier in life [3] .
Heterosubtypic antibodies, i.e. antibodies recognizing hemagglutinins from different subtypes, are rare [4] : in human pre-vaccination sera, only 0·01% of total serum IgG has been described to have heterosubtypic binding activity, one tenth of which being specific for the HA stem-epitope [4] [5] [6] . To establish the prevalence and predictors for heterosubtypic antibody responses, serum from 305 HIV-negative volunteers was collected in October 2009. In these sera we assessed both binding to five human and three non-human influenza isolates, and neutralizing antibody titers to five human and four non-human influenza isolates. These data were put into relation with epidemiological information acquired with a questionnaire at the blood draw.
Methods Procedures
Sera from 305 randomly selected healthy volunteers were prospectively collected in Zurich, Switzerland, in late 2008 before the arrival of the H1N1 pandemic (H1pdm/09). The study was approved by the ethics committee of the University Hospital Zurich and written informed consent was obtained from all study participants. Self-reported demographic data including age, sex, travel history, the total number of estimated previous influenza vaccinations, estimated times of influenza infections (defined as 'flu' with more than three bedridden days and high fever), and potential contact to influenza-infected birds were collected on the day of the blood draft (an English translation of the questionnaire is given in the supplementary methods section). As antibodies binding to avian or extinct human HA subtypes are bona-fide cross-reactive, we determined binding antibody titers to recombinant trimeric HA protein from rH1pdm/09, rH2/57, rH4/56, rH5/04, rH7/79 and rH12/76 by ELISA and put them into relation to homotypic antibodies to rH1/34 and rH3/99. In addition, we assessed whether antibodies binding to recombinant protein can also bind immobilized purified H7N7 virions (H7vir/79, suppl. figure 3) . The half-maximal effective dose (EC50) was then determined by non-linear regression of optical density (OD) values, and used for statistical analyses as well as to establish correlations with the information collected in questionnaire.
Strains used for neutralization assays are described in the supplementary data. For evaluation, the reciprocal 50% inhibitory dose was determined by non-linear regression to the logarithm of serum concentration (-log(IC50)), where possible. If most samples did not reach signal saturation, and constrained non-linear regression would have been prone for fitting artifacts, the inhibition percentage at the second serum dilution (1:90) was taken as a surrogate value. Statistical analyses were performed as outlined in the supplementary methods. R scripts used for this study are available at https://github.com/ozagordi/FluAbs.
Results
For the analysis of the prevalence and predictors of heterosubtypic antibodies, a random study population was compiled (n=305; table 1). At a serum dilution corresponding to the detection level of natural antibodies [7] and a relaxed threshold (threefold over background), between 99% and 100% of individuals, depending on the antigen tested, scored positive for serum antibodies binding, including all heterosubtypic HAs. Also at more stringent conditions of 1 in 90, 98-100% of individuals scored positive. If a more stringent threshold of a half-maximal signal was applied, heterosubtypic specificity could be monitored in 32-99% (at 1 in 30) and 0·3-79% (at 1 in 90) of the participants. The corresponding values are depicted in suppl. figure 1.
With the exception of rH12/76, binding titers to the avian strains (rH4/56, rH5/04 and rH7/79) were low compared to human HAs. Low titers were also observed against rH1pdm/09 that had not yet arrived in Switzerland when the blood was collected. Titers against human rH2/57 that became extinct in 1968 were also found to be relatively low, although distributed over a wide range of values.
To determine the direct antiviral activity of these antibodies we performed in vitro neutralization assays against H1/34, H1/07, H2/57, H3/07, H3/68, H4/56, H5/04 and H7/79 viruses. The highest neutralizing titers were found against homologous human strains (H1/34, H1/07, H2/57, H3/68 and H3/07; suppl. figure 1C and table S1 ). Titers to avian H4/56 were much lower and the barely detectable neutralizing activity to H5 and H7 even prevented computation of the logIC50 values. Instead, the percentage of inhibition at the first dilution (1 in 90) was taken as comparative proxy value for these viruses (suppl. figure 1D ).
ELISA titers and neutralizing activity correlated well in that high titers in ELISA are indicative for high neutralizing activity (table S2) . Vaccinated individuals clearly displayed higher binding and neutralizing titers against human subtypes H1/34, while still showing increased titers against rH2/57, rH3/99 and H3/68 (figure 1 and 2), albeit less markedly. As highlighted in the regression analysis, some of these differences may be explained by age alone (table 2) . Vaccinated individuals also displayed significantly higher neutralizing titers against H1/07 and H3/07 than non-vaccinated individuals. They also displayed higher binding antibody titers to heterosubtypic rH1pdm/09 and rH5/04 (figure 1). Vaccination showed no or weaker effect on binding titers against the remaining three tested heterosubtypic rHAs.
The effect of age, influenza episodes and gender was also analyzed ( Binding titers to human strains all increased with age, while increasing only in two out of five non-human strains, all of these phylogenetically close to the human ones (H1pdm/09 and H5/04). Neutralizing titers were also found to increase with age in two out of five human strains tested (H2/57 and H3/68). On the other hand, titers to heterosubtypic strains did not display a dependence on age.
Similarly, vaccination showed a positive correlation in binding and neutralizing titers to most human strains, with the exception of the neutralizing titers to H3/68, which were independent of vaccination ( figure 3, table 2 ). Titers to H2/57 were distinct, as binding titers did not depend on vaccination, and neutralizing titers showed a modest interaction between age and vaccination status. Specifically, neutralizing titers to H2/57 increased with age for both vaccinated and non-vaccinated groups, but were more pronounced in the vaccinated group. As both H2 and H5 subtypes have never been included in the vaccines, the fact that vaccination had a positive correlation with neutralizing titers to these subtypes can be explained by their phylogenetic proximity to H1 subtype, which is part of the widely used split vaccine formulation.
In order to expose differences between age groups that would go undetected in linear regression, we performed loess smoothing on antibody titers in relation to age separately for vaccinated and non-vaccinated donors. Neutralizing titers to recent human isolates (H1/07 and H3/07) were higher in vaccinees, but overall not influenced by age (as already suggested by linear regression). However, non-linear regression revealed that the youngest participating donors (approximately below age 30) clearly showed the highest titers ( figure   3 ). Similar findings were made for binding titers to recently isolated H3/99. This was in contrast to the behavior observed against older isolates (H2/57 and H3/68); here the best neutralizing titers were found in those donors who were in their first decade of life when the corresponding isolate has been circulating (age 50 to 61 and age 41 to 50, respectively). The same trend emerged for binding titers to H2/57. On the other hand, for an older H1 isolate (H1/34) this effect was less pronounced for both neutralizing and binding titers.
Discussion
Our study demonstrates that heterosubtypic antibodies against influenza viruses, i. e. antibodies recognizing hemagglutinin from multiple subtypes, can be found in most exposed or immunized individuals. These findings corroborate previous findings made by biochemical analysis of a limited number of samples [4, 8] . We have found that vaccination not only enhanced antibody responses to subtypes that are currently circulating, and are therefore included in the vaccine, but also augmented binding and neutralizing antibody titers to heterosubtypic subtypes. Senior people had higher antibody titers to old homosubtypic influenza isolates than their younger counterparts, whose antibody response appeared to favor more recent isolates. Age was also found to be a predictor with a positive coefficient for higher antibody titers to heterosubtypic isolates. In contrast, the number of self-reported influenza episodes did not correlate with higher antibody titers, which, given the unreliability of the parameter, is not surprising. Moreover, since vaccinations, like influenza episodes, also accumulate with age and may not always be reported accurately, it is hard to disentangle their effect on the antibody titers. For this reason, vaccination status was reported as binary (vaccinated/non vaccinated), discarding differences in the number of vaccinations.
As the participants of our study have not recently been vaccinated, their antibody repertoire is not skewed towards a recently inoculated vaccine-strain. Attention is therefore focused on the serum antibody composition present when infection is most likely to occur. The use of viable viruses for neutralization assays rather than highly-neutralization sensitive pseudotyped virions further assured that the neutralizing activity detected is biologically relevant [9] . individuals born before 1957 had higher titers to H1pdm/09 than younger participants [11, 12] . Although the binding titers were expected to increase with age in the non-vaccinated cohort, no peak in elderly appeared in non-parametric smoothing. Both observations, however, could be explained by the low sample size in this age group (figure 3).
Since we used a novel neutralization assay we cannot give predictions for protection. In the hemagglutinin inhibition assays (HIA), a serum dilution of 1 in 40 is considered protective while comparable values were found for an ELISA-based and a colorimetric microneutralization assay (MN) but these values are not applicable to our assay [13] in particular since it was also shown that ELISA values and HIA values do not correlate, not even within the same subtypes [14] . Moreover, since the majority of heterosubtypic antibodies was found to bind a conserved epitope in the stem of the HA protein and did not interfere with hemagglutination [15, 16], they would not be detected by HIA. Consequently, no direct predictions for heterosubtypic protection can be drawn from our dataset at this point. Further research will be required to define this relationship.
In contrast, the large number of serum samples tested for both binding and neutralization allowed us the establishment of a linear relationship: increasing titers of binding antibodies correlate statistically significant with increasing neutralizing titers (table S2). The correlation coefficient R for extinct human strains was reasonable high especially in rH2/57 vs. H2/57 (R=0·43), whereas isolates with very distant isolation years, H3/68 vs. rH3/99 did not correlate at all, despite belonging to the same subtype.
Lessler and colleagues found that repeated exposure to different H3N2 strains increased antibody titers to those strains encountered earlier in life while progressively fewer specific antibodies to subsequent infection are made with age [3] . We could confirm this finding in that the neutralizing and binding titers were the highest in those individuals who were in their first decade of life during the period of time when the corresponding subtype was circulating. Older individuals also had significantly more binding and neutralizing antibodies against old than more recent isolates (e.g. H3/99; suppl. figure 2), which may reflect original antigenic sin [17] . In contrast, in line with other studies [18] we found antibody titers to the last pre-study isolates ('07) to be the same in all age groups.
In elderly individuals, vaccination increased the probability of having heterosubtypic antibodies. Thus, while senescence of the immune system presumably contributed to a poorer response to recent isolates, age was advantageous for the development of heterosubtypic antibodies (to both human and non-human isolates). Vaccination always improved titers in the oldest or middle age group compared to young individuals. Although the age at which the vaccinations were received was not assessed, most individuals received them in the previous 5-10 years. In fact, influenza vaccination was very uncommon in Switzerland prior to the late nineties. [19] . Our findings show that vaccination is of value also in more seasoned individuals, and that its benefit is not just the result of vaccinations at younger age. This provides additional, albeit indirect, support for annual vaccinations in elderly. 
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Robust linear regressions in figures 4-7 were computed with rlm (MASS package), smoothing with loess (stats package) and displayed with ggplot2. Smoothing is noisier in proximity of the endpoints. Since the smoothing is done on less data, few points can influence the estimate heavily. For this reason the confidence regions grow at the borders, and one must be cautious in not over interpreting this behavior.
Regression analysis of the full model was performed with glm (stats package).
In a first analysis, linear regression was performed separately on vaccinated and non-vaccinated donors with the model: binding titer = intercept + α × age. By estimating the age effect separately, potential distortions induced by repetitive trivalent inactivated influenza vaccinations (TIV) could be assessed.
Including the vaccination status as a covariate allowed us to simultaneously estimate the effect of age and vaccination and a potential interaction between them. To this end, we started estimating the coefficients of the full model: binding titer = intercept + α × age + β × vaccination + γ × age × vaccination, where the age is given in years and vaccination is a binary dummy variable. In order to avoid over fitting, the complexity of the model was iteratively reduced by removing the coefficients not significantly different from zero and re-estimating the others. We required the pvalue for the regression coefficients to be lower than 1% in order to keep them in the model. This informal calibration of the significance threshold also constitutes an attempt to address the multiple testing issue [2] .
Scripts used for this study are available at https://github.com/ozagordi/FluAbs
Blood samples
Full blood was allowed to coagulate at RT for at least 30 min before serum was collected by centrifugation (at 20 °C at 2'500 x g for 15 min), and stored in 1mL aliquots at -80 °C. Before use, aliquots of sera were thawed and heat inactivated at 56 °C for 30 min and supplemented with 0.1% NaN3 as preservative. Heat inactivated serum was stored at 4 °C.
Cells
Madin Darby canine kidney (MDCK) cells were purchased from the American Type Culture Collection (ATCC®: CCL-34™) and used for all cell-based assays. Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with heat inactivated 10% fetal bovine serum, and 50 U/mL penicillin and 50 µg/mL streptomycin.
Virus preparation and concentration
Influenza viruses were propagated either on MDCK or in d11 embryonated hen eggs, and harvested 24 to 48 h (MDCK cells) or 48 h (eggs) post infection. For ELISA using virions from A/FPV/Bratislava/79(H7N7) (H7vir/79), virus was collected from cell supernatant by ultracentrifugation through a 32% sucrose cushion (2 h at 4 °C at 28'000 rpm; swing out rotor SW28). The HA-constructs were either generated from viral RNA according to Hoffman or de novo synthesis according to the published sequence or by already cloned cDNAs received from other labs [3] . In brief, viral RNA was isolated from cell supernatant using RNeasy Mini Kit columns (Qiagen).
Generation of recombinant HA
Following reverse transcription using Superscript II reverse transcriptase (Invitrogen) and a forward primers specific for segment 4. Segment 4, containing the HA gene, was then amplified by PCR using segment 4-specific degenerated primer. After subcloning of the amplified cDNA into the pcDNA 3.1 vector (Invitrogen) and sequencing, the ORF was modified for baculovirus expression as described in Stevens et al. [4] .
rHAs, stabilized by a his-tagged trimerization domain, were expressed into the supernatant of Baculovirus infected SF9 cells at 28 °C and harvested 4 d post infection. Soluble HA was recovered from the cell supernatant by metal affinity chromatography using NiNTA beads (GE Healthcare). [5] Fractions containing HAs were pooled and concentrated with Centrifugal Filter Unit (Ultra-15
Ultracel-10 membrane, Amicon) proteolytically processed into HA1 and HA2 with 10 U/µg HA of TPCK-treated trypsin (Sigma Aldrich) at RT for 1 h. Trypsin was removed by size exclusion chromatography on Superdex S200 slurry (GE Healthcare) and fractions containing HA trimers were collected and concentrated.
ELISA
96-well Corning® half-area polystyrene high binding microplates (Costar) were coated with 25 µl of 1 µg/mL HA in PBS at 4 ⁰C for 64 h. Coated plates were then blocked with 3% BSA in PBS for at least 1h at RT. Sera were titrated in 1% BSA/PBS, and allowed to bind for 1 h. After washing with 0.01% Tween/TBS, bound serum IgG was detected with HRPO-coupled a goat anti-human fab-HRP antibodies (Jackson Immuno). The assay was developed for 12 min using 50 µL TMB (2 mg/mL) / H2O2 (5 µL/mL) in 0.1 M NaH2PO4 * H2O as a chromogenic substrate before the reaction was stopped by the addition of 50 µL 2 N H2SO4. After determining absorption at 450 nm, the serum dilutions giving half maximal absorbance was determined by non-linear regression of the measured OD values to the logarithmized serum concentration using the Hill-Curve as equation template. If no fit could be obtained, i.e. when an individual sample did provide sufficient data points for an accurate fit, top and bottom values were constrained to the corresponding average values determined over the whole assay fitting data to sigmoid dose response curves (variable slope) using GraphPad Prism 5 and 6 and Excel
(Microsoft).

Neutralization assay
Strains used for neutralization assays were A/Puerto Rico/8/34(H1N1) (H1/34), supplemented DMEM containing 0.2 % BSA (DMEM/BSA) with the help of a semi-automated pipetting system (BioTek Precision). The virus-sera mix was incubated at 37 °C for 1 h and transferred to the cells, where non-neutralized virus was allowed to infect cells for 1 h at 37 °C. The virus-serum mix was then removed, plates washed with PBS and DMEM/BSA added. Viral protein synthesis was allowed to proceed for 6-7 h before cells were fixed and permeabilized with 100% methanol. Cells were then stained with FITC-labeled anti-NP antibody (3 µg/ml), H16-L10-4R5
(ATCC No. HB-65™), in PBS containing 1% BSA at 4 °C over night, followed by nuclear staining using Hoechst dye (Molecular probes). Fluorescence or both FITC and Hoechst were measured by a Perkin
Elmer plate reader at 16 different locations in each well to account for variation in the local cell densities. The average from the individual measuring points was used to calculate the half maximal inhibitory concentration (IC50) were determined using the same approach as described for EC50.
For H5 and H7 low heterosubtypic neutralizing activity was found in sera that prevented computation of the logIC50. Instead, the inhibition percentage at the first dilution (1 in 90) was taken as comparative value.
